Sugi Predict
/ Targets
/ CDKL1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to CDKL1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
PHASE4 | COMPLETED |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) |
PHASE3 | COMPLETED |
| Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old |
PHASE3 | NOT_YET_RECRUITING |
| A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer |
PHASE3 | ACTIVE_NOT_RECRUITING |
| Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression |
PHASE2 | COMPLETED |
| Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 |
PHASE2 | RECRUITING |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) |
PHASE1/PHASE2 | RECRUITING |
| CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer |
PHASE2 | COMPLETED |
| Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma |
PHASE1/PHASE2 | RECRUITING |
| Avelumab, Palbociclib and Axitinib in Advanced RCC |
PHASE2 | WITHDRAWN |
| A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors |
PHASE1/PHASE2 | COMPLETED |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer |
PHASE2 | WITHDRAWN |
| Abemaciclib + Pembrolizumab In Glioblastoma |
PHASE2 | WITHDRAWN |
| Palbociclib With Everolimus + Exemestane In BC |
PHASE1/PHASE2 | COMPLETED |
| An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. |
PHASE1/PHASE2 | COMPLETED |
| Genetic Testing in Guiding Treatment for Patients With Brain Metastases |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC |
PHASE2 | ACTIVE_NOT_RECRUITING |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy |
PHASE2 | COMPLETED |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer |
PHASE2 | RECRUITING |
| Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies |
PHASE1 | RECRUITING |
| Study of FCN-437c in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms |
PHASE1 | COMPLETED |
| Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma |
PHASE1 | COMPLETED |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy |
PHASE1 | RECRUITING |
| A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers |
PHASE1 | COMPLETED |
| Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period |
nan | UNKNOWN |
| The SONImage Study |
nan | ACTIVE_NOT_RECRUITING |
Related proteins — ESM-2 sequence neighbours (a CDKL1 binder may also engage these)